News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Profectus BioSciences, Inc. Awarded Follow-on Grant from PATH Malaria Vaccine Initiative (MVI)


11/15/2011 9:31:59 AM

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today it has received a commitment of additional funding from the PATH Malaria Vaccine Initiative (MVI). The funds will support proof-of-concept studies in non-human primates with proprietary, plasmid DNA (pDNA, delivered using the electroporation (EP) based TriGrid™delivery system (TriGrid) developed by Ichor Medical Systems) and recombinant vesicular stomatitis virus (rVSV) vector technologies towards the development of a preventive malaria vaccine.

Read at BioSpace.com


comments powered by Disqus
   
Malaria

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES